Exposing the secrets of the ashwagandha industry

Maybe you’ve tried Ashwagandha before, felt nothing and binned it. Or perhaps you’re taking it now, not entirely sure if it’s actually doing anything, but you keep going because reddit told you to give it eight weeks.

You're not imagining the lack of results. There are real, documented reasons why most ashwagandha supplements underdeliver. Two of them in particular don't get talked about nearly enough. Let’s uncover the dirty underbelly of the Ashwagandha industry together.

Every brand is selling you the same thing

Most supplement companies don’t want to tell you this information, so we will: the ashwagandha in their capsule almost certainly came from one of three suppliers.

The market is dominated by three licensed extracts, and you’ve already heard of them. KSM-66, made by Ixoreal Biomed. Sensoril, made by Natreon (now Kerry). And Shoden, made by Arjuna Natural. Between them, these three ingredients account for the vast majority of branded ashwagandha products you'll find online or on a shelf.

So when you're comparing Brand A's Ashwagandha to Brand B's, you're often comparing identical raw materials in different packaging. The label looks different, the price is different. But the powder inside the capsule? Same supplier, same spec sheet, same extract.

KSM-66 is standardised to a minimum 5% withanolides from root only. Sensoril uses root and leaf, hitting around 10% withanolides. Shoden concentrates withanolide glycosides to 35%, using root and leaf. These numbers get printed on labels and used in marketing as if they tell you everything you need to know about the product.

They tell you almost nothing about what happens after you swallow it.

Your body can't use most of what's on the label

Withanolides are the active compounds in ashwagandha. They're the reason you're taking it. The percentage on the label tells you how much is in the capsule, but it says nothing about how much actually reaches your bloodstream.

For most ashwagandha extracts, that number is genuinely poor.

A study published in the Journal of Advanced Pharmaceutical Technology & Research tested the intestinal permeability of individual withanolides using an in vitro absorption model. Some compounds, like withanolide A and withanone, showed decent permeability. The glycosylated forms (withanoside IV and V) showed low permeability. And withaferin A, widely considered the most biologically active withanolide in ashwagandha? Essentially impermeable.

The compound that a lot of the clinical interest is built around can barely cross your gut wall. And it’s not talked about enough.

A separate human pharmacokinetic study found withaferin A's oral bioavailability at roughly 5%. A phase I dose escalation trial couldn't detect it in blood plasma at all, even at the highest dose tested. Mouse data put oral bioavailability at 1.8%.

Then there's the 2025 crossover study published in Current Therapeutic Research. Researchers compared four different ashwagandha extracts, each standardised to deliver 185mg of total withanolides. Matched on paper. In practice, absorption varied enormously between them. The conclusion: the type of withanolide matters far more than the total amount. Withanolide glycosides absorbed significantly better than non-glycosylated forms.

This is what the industry glosses over. A higher withanolide percentage on a label does not mean better results. If those withanolides aren't in a form your body can absorb, what are you actually paying for?

A note on safety

It would be dishonest to write about ashwagandha without mentioning the safety questions that have surfaced in recent years. The NIH's Office of Dietary Supplements notes that while ashwagandha appears well tolerated for up to three months, there are case reports of liver injury in some individuals. The UK's Food Standards Agency and several EU regulatory bodies have also flagged potential associations with thyroid disruption and are currently reviewing ashwagandha's safety profile. These cases are rare, and large clinical safety trials haven't replicated the findings, but they're worth knowing about if you have pre-existing liver or thyroid conditions.

Concentration has a ceiling

You might think the answer is to pack more withanolides into a smaller dose, makes sense right? That's essentially what Shoden does, and we'll give credit where it's due: with 35% withanolide glycosides, Shoden genuinely does improve upon the absorption problem compared to its competitors. The 2025 crossover study backs this up. Its glycoside-rich profile translated to measurably higher plasma levels than extracts with similar total withanolide content but different compositions.

But there's a limit to what concentration alone can achieve. You can increase the input, but if those compounds still hit the same absorption bottleneck at the intestinal wall, you're getting diminishing returns. Better raw material, same delivery problem.

What we did differently

Ashwagandha Elite isn't a licensed extract in a Predator tub. It's a whole plant root and leaf extract standardised to 11.41% withanolides (verified by HPLC), complexed with HPβCD, a cyclodextrin delivery compound that's been used in pharmaceutical drug formulations for years to improve the absorption of poorly soluble compounds.

The mechanism is straightforward, so without boring you to death with the science, here’s the basics. Cyclodextrins are ring-shaped molecules with a water-repelling interior and a water-attracting exterior. The withanolide compound sits inside the ring, which protects it from degradation in the gut and makes the whole complex soluble enough to cross the intestinal wall. This isn't something the supplement industry came up with. HPβCD is an FDA-approved pharmaceutical excipient used in drug delivery systems, nasal sprays, and injectable formulations. It exists because pharmaceutical companies ran into the exact same absorption problem and needed to solve it.

How much difference does it make? The research on HPβCD complexes with other poorly absorbed compounds gives you a decent indication. Curcumin, which has similar absorption problems to withanolides, showed a roughly 2.8x increase in oral bioavailability when complexed with HPβCD in rat pharmacokinetic studies. The flavonoid naringenin saw an 11-fold increase in membrane permeability. Griseofulvin, a notoriously poorly absorbed antifungal, showed a 4-6x bioavailability improvement with cyclodextrin delivery. The typical range across the published literature sits between 3x and 10x improved uptake, depending on the compound. That's the range we're working within.

The withanolide percentage on our label is lower than Shoden's. We know that, and we're not pretending otherwise. The point was never to win a numbers game on the supplement panel. It was to make sure what's in the capsule ends up where it needs to be, in your bloodstream, doing the job you bought it for.

If you've tried ashwagandha before and written it off, the extract probably wasn't the issue. The delivery was. Why not try our Ashwagandha Elite formulation and experience the difference?